Maiti Soumyajit, Ali Kazi M, Jana Kishalay, Chatterjee Kausik, De Debasis, Ghosh Debidas
Department of Bio Medical Laboratory Science and Management with Clinical Nutrition Unit (U.G.C. Funded Innovative Department), Vidyasagar University, Midnapore, West Bengal, India.
J Nat Sci Biol Med. 2013 Jan;4(1):68-73. doi: 10.4103/0976-9668.107263.
Syzygium jambolanum (S jambolanum) is widely used in homeopathy for treating patients with diabetes mellitus. In the present study, an attempt has been made to investigate the remedial effect of homeopathic drug S jambolanum on carbohydrate and lipid metabolic disorders on streptozotocin induced diabetic rat.
Diabetes induction in Wistar strain rat was performed as per standard method using streptozotocin at the dose of 4 mg/100 gm body weight. Activities of carbohydrate metabolic enzymes in hepatic tissue, and glycogen content in hepatic and muscular tissues were assessed biochemically following the standard protocols. Serum lipid profile level and activities of GOT and GPT in serum were measured as per standard method using specific kits.
The homeopathic drug, mother tincture of S jambolanum significantly decreased fasting blood glucose levels and improved carbohydrate metabolic key enzyme activities in hepatic tissue i.e., hexokinase, glucose-6-phosphate dehydrogenase and glucose-6-phosphatase in diabetic rats. Alongside, serum lipid profile biomarkers i.e., triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDLc), very low density lipoprotein cholesterol (VLDLc) and high density lipoprotein cholesterol (HDLc) levels were significantly ameliorated in homeopathic drug supplemented diabetic animals in compared with the untreated diabetic animal. Side by side, the S jambolanum has the capacity to attenuate diabetes induced hepatic injury in model animal, which has been assessed here by the recovery of GOT and GPT activities in serum of drug treated diabetic animal.
The result of the present study indicated that the homeopathic drug S jambolanum (mother tincture) has a protective effect on diabetic induced carbohydrate and lipid metabolic disorders in STZ-induced diabetic animal.
乌墨（Syzygium jambolanum）在顺势疗法中被广泛用于治疗糖尿病患者。在本研究中，已尝试研究顺势疗法药物乌墨对链脲佐菌素诱导的糖尿病大鼠碳水化合物和脂质代谢紊乱的治疗作用。
按照标准方法，以4 mg/100 g体重的剂量使用链脲佐菌素对Wistar品系大鼠进行糖尿病诱导。按照标准方案通过生化方法评估肝组织中碳水化合物代谢酶的活性以及肝组织和肌肉组织中的糖原含量。使用特定试剂盒按照标准方法测量血清脂质谱水平以及血清中谷草转氨酶（GOT）和谷丙转氨酶（GPT）的活性。
顺势疗法药物乌墨母酊显著降低了糖尿病大鼠的空腹血糖水平，并改善了肝组织中碳水化合物代谢关键酶的活性，即己糖激酶、葡萄糖-6-磷酸脱氢酶和葡萄糖-6-磷酸酶。与此同时，与未治疗的糖尿病动物相比，补充顺势疗法药物的糖尿病动物的血清脂质谱生物标志物，即甘油三酯（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDLc）、极低密度脂蛋白胆固醇（VLDLc）和高密度脂蛋白胆固醇（HDLc）水平得到了显著改善。此外，乌墨具有减轻模型动物糖尿病诱导的肝损伤的能力，这在此处通过药物治疗的糖尿病动物血清中GOT和GPT活性的恢复来评估。
本研究结果表明，顺势疗法药物乌墨（母酊）对链脲佐菌素诱导的糖尿病动物糖尿病诱导的碳水化合物和脂质代谢紊乱具有保护作用。
